Literature DB >> 9806462

Monitoring of inhibitors of enzymatic amplification in polymerase chain reaction and evaluation of efficacy of RNA extraction for the detection of hepatitis C virus using the internal control.

H Miyachi1, A Masukawa, T Ohshima, H Fusegawa, T Hirose, C Impraim, Y Ando.   

Abstract

Inhibitors of enzymatic amplification in serum may cause false-negative results for direct detection of hepatitis C virus (HCV) by polymerase chain reaction (PCR). This study was undertaken to demonstrate the importance of the internal control in a PCR assay for detection of HCV-RNA to monitor false-negatives due to inhibitors. HCV-RNA was extracted using RNA extraction kit (SepaGene RV-R, Sanko Junyaku) and a prototype instrument for automated specific capture of HCV-RNA with probes and magnetic bead/fluid separation (Roche Molecular Systems). The extracted HCV-RNA and internal control were detected by an automated PCR machine (Cobas Amplicor, Roche Diagnostic Systems). Addition of hemoglobin (up to 4.5 g/l) to the sera followed by RNA extraction with SepaGene RV-R had no inhibitory effect on the detection of either HCV-RNA or the internal control. In contrast, addition of heparin to the sera showed an inhibitory effect with a dose-dependent manner on the detection of both HCV-RNA and the internal control, with a greater effect at lower copy number of HCV. When HCV-RNA was extracted by the automated system, the inhibitory effect of heparin was successfully eliminated. In the assays of 65 serum samples positive for anti-HCV antibodies, positivity for the internal control indicated efficient amplification and validated 14 negative and two equivocal results for detection of HCV-RNA. Detection of the internal control was negatively correlated with viral copy number in sera suggesting competitive inhibition of high viral copy number on amplification of the internal control. Extraction, co-amplification and detection of the internal control appears useful for estimating effects of inhibitors on amplification in each assay for the detection of HCV-RNA, and for evaluating efficacy of RNA extraction methods.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806462     DOI: 10.1515/CCLM.1998.098

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Anticoagulants interfere with PCR used to diagnose invasive aspergillosis.

Authors:  Marta E García; Jose L Blanco; Jesús Caballero; Domingo Gargallo-Viola
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Automated specific capture of hepatitis C virus RNA with probes and paramagnetic particle separation.

Authors:  H Miyachi; A Masukawa; T Ohshima; T Hirose; C Impraim; Y Ando
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Inhibition monitoring in veterinary molecular testing.

Authors:  Lifang Yan; Kathy L Toohey-Kurth; Beate M Crossley; Jianfa Bai; Amy L Glaser; Rebecca L Tallmadge; Laura B Goodman
Journal:  J Vet Diagn Invest       Date:  2019-11-18       Impact factor: 1.279

4.  Quantitative assay of hepatitis C virus RNA using an automated extraction system for specific capture with probes and paramagnetic particle separation.

Authors:  Hayato Miyachi; Atsuko Masukawa; Satomi Asai; Toshiaki Miura; Shigeru Tamatsukuri; Toru Hirose; Yasuhiko Ando
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

5.  Association between oral anticoagulants and COVID-19-related outcomes: a population-based cohort study.

Authors:  Angel Ys Wong; Laurie Tomlinson; Jeremy P Brown; William Elson; Alex J Walker; Anna Schultze; Caroline E Morton; David Evans; Peter Inglesby; Brian MacKenna; Krishnan Bhaskaran; Christopher T Rentsch; Emma Powell; Elizabeth Williamson; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; Jonathan Cockburn; Helen I McDonald; Rohini Mathur; Kevin Wing; Harriet Forbes; Rosalind M Eggo; Stephen Jw Evans; Liam Smeeth; Ben Goldacre; Ian J Douglas
Journal:  Br J Gen Pract       Date:  2022-06-30       Impact factor: 6.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.